Alnylam Pharmaceuticals, Inc.  

(Public, NASDAQ:ALNY)   Watch this stock  
Find more results for ALNY
84.25
+2.83 (3.48%)
Real-time:   3:42PM EDT
NASDAQ real-time data - Disclaimer
Currency in USD
Range 81.28 - 85.10
52 week 31.38 - 86.92
Open 81.28
Vol / Avg. 459,142.00/743,515.00
Mkt cap 7.73B
P/E     -
Div/yield     -
EPS -5.12
Shares 91.73M
Beta 2.95
Inst. own 96%
Oct 31, 2017
Q3 2017 Alnylam Pharmaceuticals Inc Earnings Release (Estimated) - 4:00PM EDT - Add to calendar
Sep 13, 2017
Alnylam Pharmaceuticals Inc at Morgan Stanley Healthcare Conference - 9:55AM EDT - Add to calendar
Sep 12, 2017
2017 RNAi Roundtable: Fitusiran, in development for the treatment of hemophilia and rare bleeding disorders - 10:30AM EDT - Add to calendar
Sep 7, 2017
2017 RNAi Roundtable: Givosiran, in development for the treatment of acute hepatic porphyrias - 10:30AM EDT - Add to calendar
Aug 23, 2017
2017 RNAi Roundtable: Platform advances in RNAi therapeutics - 3:30PM EDT - Add to calendar
Aug 9, 2017
Q2 2017 Alnylam Pharmaceuticals Inc Earnings Call - Webcast
Aug 9, 2017
Q2 2017 Alnylam Pharmaceuticals Inc Earnings Release
Aug 9, 2017
2017 RNAi Roundtable: Revusiran investigation results - Webcast
Aug 3, 2017
2017 RNAi Roundtable: Patisiran, in development for the treatment of hereditary ATTR amyloidosis - Webcast
Jul 10, 2017
Alnylam Pharmaceuticals Inc and Sanofi Genzyme to Discuss Fitusiran Phase 2 OLE Results - Corporate Call - Webcast
More events from DailyFinance »    

Key stats and ratios

Q2 (Jun '17) 2016
Net profit margin -743.28% -869.63%
Operating margin -756.18% -900.33%
EBITD margin - -868.25%
Return on average assets -36.99% -30.96%
Return on average equity -48.62% -37.54%
Employees 514 -
CDP Score - -

Address

300 3rd St
CAMBRIDGE, MA 02142-1103
United States - Map
+1-617-5518200 (Phone)
+1-617-5518101 (Fax)

Website links

External links

Analyst Estimates - MarketWatch
SEC Filings - EDGAR Online
Major Holders - MSN Money

Description

Alnylam Pharmaceuticals, Inc. is a biopharmaceutical company. The Company is engaged in the discovery, development and commercialization of ribonucleic acid (RNA) interference (RNAi) therapeutics. The Company is focused on the use of its N-acetylgalactosamine (GalNAc)-conjugate platform for delivery of small interfering RNAs (siRNAs). Its pipeline of investigational RNAi therapeutics focuses on three Strategic Therapeutic Areas (STArs): Genetic Medicines, with multiple product candidates for the treatment of rare diseases; Cardio-Metabolic Diseases, with product candidates directed toward genetically validated, liver-expressed disease targets for unmet needs in cardiovascular and metabolic diseases, and Hepatic Infectious Diseases, with product candidates designed to address the global health challenges of hepatic infectious diseases, beginning with hepatitis B and hepatitis D viral infections. The Company's lead product, Patisiran, is formulated utilizing lipid nanoparticles (LNPs).

Officers and directors

Michael W. Bonney Independent Chairman of the Board
Age: 58
Bio & Compensation  - Reuters
Barry E. Greene President
Age: 53
Bio & Compensation  - Reuters
Trading Activity - Yahoo Finance
John M. Maraganore Ph.D. Chief Executive Officer, Director
Age: 54
Bio & Compensation  - Reuters
Manmeet S. Soni Chief Financial Officer, Senior Vice President, Principal Financial Officer
Age: 39
Bio & Compensation  - Reuters
Yvonne L. Greenstreet M.D. Chief Operating Officer, Executive Vice President
Age: 54
Bio & Compensation  - Reuters
Akshay K. Vaishnaw M.D., Ph.D. Executive Vice President - Research and Development
Age: 54
Bio & Compensation  - Reuters
Laurie B. Keating Senior Vice President, General Counsel, Secretary
Age: 62
Bio & Compensation  - Reuters
Pushkal Garg M.D. Senior Vice President - Clinical Development, Chief Medical Officer
Bio & Compensation  - Reuters
Theresa Heggie Senior Vice President, Head of Europe and Canada
Age: 57
Bio & Compensation  - Reuters
Peter F. Smith Ph.D. Senior Vice President - Early Development
Age: 59
Bio & Compensation  - Reuters